, I mean some aspect of a deal that is too severe in risk and nature to allow the deal to continue. There are a few black and white private equity deal killers, but also many shades of grey.
We all have our own biases and this is especially true for the private equiteer who has sourced a deal. We look for reasons to do the deal and downplay the reasons not to.
The solution to this is to have a set list of deal killers and to stick to that list regardless. The problem of course is that you could miss great deals and there’s merit in looking at deals on a case-by-case basis. But I’m sticking by
, because you simply don’t need to take undue risk. The following list is not exhaustive, but outlines a few scenarios in which I’d kill a deal (and after all, there’s a rank and file in a private equity firm for a reason):
I know I’ve been quite opinionated in this post and I concede that in a day, week or month, I may change my mind on some of these issues. But, I’ve witnessed a lot of self-fulfilling analysis lately and think it’s important to maintain objectivity in this climate. As the cliché says:
. That is, if the deal looks like a lemon early, it probably is a lemon.
Capital Expenditure (Capex), which simply means expenditure on assets with long lives, is a big deal for private equity. Firstly, because it reduces cash flow. Secondly, because it reduces cash flow. Thirdly, okay, okay… I don’t want to harp on about cash flow, but I do want to talk about the importance of capital expenditure
Read More
It is often mused that the success of an investment is directly proportionate to the rigor of the initial analysis. Whether this is true or not (there’s always the risk of analysis paralysis), private equity firms expend an inordinate amount of effort on determining the viability of a potential investment. The following list, although not
Read More